This increase in NFIB expression is puzzling in that NFIB was recently identified as a new oncogene in small cell lung cancer [36,37,38] and most particularly in triple negative breast cancer (TNBC), where it contributes to cell proliferation/survival through a direct suppression of p21 transcription [39]. Here, NFIB is linked to triple-negative breast carcinoma.